Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Scientific Reports|June 17, 2022
Retrospective analysis of different therapeutic approaches for retroperitoneal duodenal perforationsCan Yurttas, Christian Thiel, Dörte Wichmann, et al.BMC Gastroenterology|November 22, 2021
Endoscopic negative pressure therapy as stand-alone treatment for perforated duodenal diverticulum: presentation of two casesDörte Wichmann, Kai Tobias Jansen, Flurina Onken, et al.Journal of Clinical Medicine|April 27, 2024
Fluorescence-Guided Laparoscopy after Oral Hypericin Administration for Staging of Locally Advanced Gastric Cancer-A Pilot StudyCan Yurttas, Philipp Horvath, Imma Fischer, et al.Cancers|January 23, 2024
Efficacy of Different Oncolytic Vaccinia Virus Strains for the Treatment of Murine Peritoneal MesotheliomaCan Yurttas, Julia Beil, Susanne Berchtold, et al.Journal of Leukocyte Biology|January 29, 2024
High-dimensional in situ proteomics imaging to assess γδ T cells in spatial biologyNicola Herold, Matthias Bruhns, Sepideh Babaei, et al.Cancers|March 10, 2022
Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis ModelNick Seyfried, Can Yurttas, Markus Burkard, et al.Journal for Immunotherapy of Cancer|December 22, 2021
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapyJonas Bochem, Henning Zelba, Janine Spreuer, et al.Oncogene|May 26, 2026
An ex vivo permissivity assay to assess replication of the oncolytic virus VSV-GP in patient-derived tumor samplesBenjamin Schoeps, Stefanie Estermann, Susanne Berchtold, et al.Nature Cancer|January 17, 2025
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancerRamona Rudalska, Jule Harbig, Michael Forster, et al.Journal for Immunotherapy of Cancer|January 20, 2026
Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanomaNicola Herold, Jonas Bochem, Johanna Leyens, et al.Pageof 3